|
Study/name of the trial | Study design | Number of patients | Type of GN | Cell type | Delivery method | Cell dose | Follow-up period | Outcomes | Side effects in cell-treated patients | Reference number |
|
Jayne et al. (2004) | Nonrandomized, uncontrolled study | 53 (33 had nephritis) | LN | Autologous hematopoietic stem cell | Vein infusion | | 26 (0–78) months | Stabilization or improvement in renal function; no patients developed new renal involvement | No major complications reported | [43] |
|
Thirabanjasak et al. (2010) | Case report | 1 | LN | Autologous hematopoietic stem cell | Renal injection | | | No improvement in renal function | Development of angiomyeloproliferative lesions at the sites of infection when 3 month after cell therapy | [33] |
|
El-Ansary et al. (2012) | Nonrandomized, uncontrolled study | 10 | LN | Mesenchymal stem cell | Infusion intravenously | 0.7– cell/kg in two divided doses 1 week apart | 6 months | ↓Scr ↑creatinine clearance | No major complications reported | [29] |
|
Belingheri et al. (2013) | Case report | 1 | FSGS | Human allogeneic bone marrow mesenchymal stem cells | Vein infusion | cell/kg | 22 months | Normal and stable renal function (Scr↓, GFR↑) | No major complications reported | [44] |
|
Su et al. (2013) | Nonrandomized, uncontrolled study | 5 (kidney involved in 4) | LN | Autologous peripheral blood hematopoietic stem cell | Vein infusion | | 40–83 months | All went into clinical remission in 3–6 months; two recurred at the end of follow-up period | No major complications reported | [45] |
|
Alchi et al. (2013) | Nonrandomized, uncontrolled study | 28 (17 had nephritis) | LN | Haematopoietic stem cell transplantation | Infusion intravenously | | 38 months | ↑improvement in renal function | No major complications reported | [46] |
|
Rampino et al. (2011) | Case report | 1 | Renal ANCA-associated vasculitis | Bone marrow mesenchymal stromal cells | Infusion intravenously | cell/kg | 12 months | Clinical remission | No major complications reported | [18] |
|